ONE GOAL:
A NEW TB DRUG
A GLOBAL EMERGENCY…
In 1993, the WHO declared tuberculosis (TB) a global health emergency. Ten years later, the problem is even worse, claiming more than 5,000 lives every day. TB’s resurgence has largely been driven by the HIV/AIDS epidemic and kills one in three people co-infected with HIV/AIDS. With two-thirds of TB patients failing to receive adequate treatment, we now not only have the highest levels of TB infection in history but that number is growing.

…IS OVERWHELMING OUT-OF-DATE DRUGS…
TB treatment relies on drugs that are up to 50 years old and takes six to nine months to complete. Many patients fail to complete treatment, so they are not cured. They continue to spread the disease and can develop drug-resistant strains, which require two years of aggressive chemotherapy to treat, without guarantee of a successful cure.

…and shows no sign of letting up.
If current trends continue over the next 20 years, there will be 1 billion new TB infections and 36 million people will die—one every 9 seconds. An affordable, faster-acting TB drug could effectively treat thousands more patients by reducing the time of therapy, combating drug-resistant strains and improving treatment of latent TB.
IT'S TIME FOR A FASTER CURE
WE ARE

JOINING FORCES TO CATALYZE SCIENCE AND INDUSTRY

The challenges of tuberculosis have tested the best scientific minds since the TB bacillus was first identified in 1882. Today, with one-third of the world infected, there has never been a greater need to apply recent breakthroughs in science and modern drug discovery methods to this reemerging threat. Speeding progress after forty years of delay in TB drug development means every scientific path must be explored and every lead uncovered. The Global Alliance for TB Drug Development (TB Alliance) is forging unique partnerships and introducing streamlined processes to catalyze this global effort. To build our portfolio, we engage expertise and resources in every discipline worldwide from academia, industry and public laboratories.

Rick O'Brien
U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
CHAIR, TB ALLIANCE SCIENTIFIC ADVISORY COMMITTEE

“To speed drug development for a faster cure, the world must collectively overcome the formidable scientific challenges of TB. This will take an unprecedented degree of collaboration and resource-sharing to transcend technical and national borders. The Scientific Advisory Committee evaluates every scientific lead, seeking opportunities that leverage global expertise and synergies to advance the field.”
“By lending my time to the TB Alliance, GlaxoSmithKline is contributing my experience and knowledge of TB drug discovery to expedite R&D. I’m also helping the TB Alliance enlist greater participation from high-burden countries, such as the five scientists from India and South Africa whose attendance at the 2003 Gordon Research Conference on TB Drug Development was sponsored by the TB Alliance.”
RALLYING GOVERNMENTS AND POLICYMAKERS

The Global Plan to Stop TB, a roadmap to fight tuberculosis, was outlined at the turn of the millennium when the world’s nations committed to reversing the onslaught of one of humanity’s oldest diseases. The Plan places equal emphasis on the priorities of TB control and on accelerated investment in research and development for better tools, such as drugs. The Plan’s Working Group on TB Drug Development, led by the TB Alliance, acts as a forum to coordinate worldwide TB research and development activities for novel therapeutics. The result of these efforts—a new, faster-acting, affordable TB drug—will save millions of lives, improve global prosperity and reduce healthcare expenses by up to 65 percent. Reducing TB treatment to two months or less will help everyone fight the epidemic more successfully and help the war on HIV/AIDS.

Agnes van Ardenne
NETHERLANDS MINISTER FOR DEVELOPMENT COOPERATION

“The Dutch government takes its commitment to the Millennium Development Goals very seriously. Our support of the TB Alliance signals the importance of investing in TB drug development today. This task is so urgent, and the public benefit so obvious, that it requires broad and shared public investments.”

Tommy Thompson
U.S. SECRETARY OF HEALTH AND HUMAN SERVICES AND CHAIR, GLOBAL FUND TO FIGHT AIDS, TB AND MALARIA

“Investing in biomedical research and enhancing international partnerships like the Global Fund and the TB Alliance are indispensable to solving the critical health challenge presented by tuberculosis. The U.S. Government, through the Department of Health and Human Services, supports the TB Alliance’s development of faster-acting tuberculosis medicines. With our active support, the TB Alliance is building a seamless pipeline of TB drug candidates to achieve this goal.”
Now that we have the Global Plan, the world must invest in better treatment today and tomorrow. If we fail to back such a simple roadmap, future generations will remember us, not for stemming the tide, but for choosing to permit an airborne contagion to team up with HIV and sweep the globe.

Dr. LEE Jong-Wook
DIRECTOR-GENERAL
WORLD HEALTH ORGANIZATION
MOBILIZING HEALTH AND ADVOCACY COMMUNITIES

Efforts to expand TB control today are slowed by the current, lengthy treatment. Faster-acting drugs are crucial, especially in the context of TB’s triple threat: rapid spread, growing drug-resistance, and a deadly symbiosis with HIV/AIDS. Despite the highest levels of infection in history, TB does not get the attention it deserves because its victims are often poor and voiceless. The TB Alliance Stakeholders lend support to patients and health workers by mobilizing support for new TB drugs. Patients, doctors and health advocates are calling for action now to banish a disease that claims 2 million lives every year.

Winstone Zulu
TB/HIV PATIENT AND ADVOCATE, ZAMBIA

“I lost all of my brothers—four of them—to the deadly TB-HIV twin-epidemic. I can’t keep quiet, and now it’s time for TB patients to mobilize, like the HIV community. We know TB won’t take care of itself. The only way we are going to get better drugs is through efforts like the TB Alliance. We can no longer sit on the sidelines, or millions more lives will be lost.”
TB has remained a silent, global emergency for too long. A growing circle of advocates is changing that perception in capitals around the world. The U.S. Congress understands that support for TB programs abroad is not just the right thing to do, but also key to TB elimination at home. Now we need to convince policymakers that investments in new drugs have concrete dividends. A faster cure will be the cornerstone of tomorrow’s TB control. Getting us there requires investment today.”

Joanne Carter
LEGISLATIVE DIRECTOR, RESULTS, U.S.

“I refuse to watch another patient die because the drug regimen is simply too long and complicated to follow. This is why I am a Stakeholder of the TB Alliance – I have the means to advocate on a global level for investments in a faster cure. Imagine what a two-month therapy would do for the Philippines, where 75 people die every day and 36 percent of our total population is infected with TB.”

Dr. Charles Yu
PRACTICING PULMONOLOGIST AND PRESIDENT OF THE PHILIPPINES COALITION AGAINST TB (PHILCAT)
MEMBER OF TB ALLIANCE STAKEHOLDERS
WE PUT SCIENCE TO WORK

Forging unique R&D partnerships with industry, governments and academia to build a portfolio of promising drug candidates.
PA-824, the first compound acquired by the TB Alliance, has moved briskly through the R&D pipeline. Since the TB Alliance signed an exclusive license agreement with Chiron Corporation in June 2002, PA-824 has reached several important milestones in preclinical development, which address key issues of compound synthesis, toxicology and preclinical efficacy.

Early research during the discovery stage showed that PA-824 and its analogs demonstrated activity against both drug-sensitive and multi-drug resistant strains of TB, signaling possible improvements in TB treatment.

In the preclinical stage, results so far have been promising in all areas. Studies have demonstrated the feasibility of PA-824 synthesis at the larger scale required for animal and clinical trials. In extensive testing, PA-824 exhibited neither damage to genes nor toxic effects on normal metabolic or hormonal systems.

With support provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), Doris Rouse, Ph.D., Director of Global Health at the Research Triangle Institute, is the project manager of the Development Team, which includes Drs. Barbara Laughon, Christopher Lipinski, Clifton Barry, Christine Sizemore and Ken Stover of the Scientific Advisory Committee.

Dr. Rouse said, “We are excited about the progress of PA-824. At each go/no-go decision we’ve passed, we gain increased confidence. Now we want to move it as quickly as possible through the next phase of animal studies.”

Ongoing development tasks include additional animal studies to assess the safety and efficacy of PA-824. Further, the TB Alliance is working to optimize the synthesis of PA-824 to reduce production costs. If extensive animal toxicology studies in the next year are similarly successful, the TB Alliance will be able to enter Phase I clinical trials.

To ensure further development of this most promising class of drug candidate, the TB Alliance is also pursuing research into analogs of PA-824.

Status of PA-824: Meeting Key Milestones

With each milestone PA-824 passes, we gain increased confidence in the promise of this class of compounds for improving TB treatment.”

Dr. Doris Rouse, Project Manager for PA-824, Research Triangle Institute

---

### PA-824 DEVELOPMENT PLAN*

<table>
<thead>
<tr>
<th>STUDY</th>
<th>PROJECT SCHEDULE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BASELINE TECHNICAL REVIEW AND PLANNING</strong></td>
<td></td>
</tr>
<tr>
<td>Characterization</td>
<td></td>
</tr>
<tr>
<td>Hazard analysis of dinitro intermediate</td>
<td></td>
</tr>
<tr>
<td>Synthesis of GMP compound</td>
<td></td>
</tr>
<tr>
<td>Formulation development and synthesis optimization</td>
<td></td>
</tr>
<tr>
<td><strong>PRECLINICAL STUDIES</strong></td>
<td></td>
</tr>
<tr>
<td>Genotoxicity study</td>
<td></td>
</tr>
<tr>
<td>HERG assay</td>
<td></td>
</tr>
<tr>
<td>Human nuclear hormone receptor panel</td>
<td></td>
</tr>
<tr>
<td>Human CYP450 isozymes</td>
<td></td>
</tr>
<tr>
<td>14-day repeated dose tox studies</td>
<td></td>
</tr>
<tr>
<td><strong>PHARMACOKINETIC AND ADME</strong></td>
<td></td>
</tr>
<tr>
<td>IND SUBMISSION</td>
<td></td>
</tr>
</tbody>
</table>

*This chart, featuring selected studies, is a condensed version of the PA-824 development plan.

---

WHO
- Research Triangle Institute (RTI)
- ABC Laboratories
- BioReliance
- Cambridge Major Laboratories, Inc.
- EMS DOTTIKON
- The John Hopkins University
- MDS Pharma
- National Institute Of Allergy and Infectious Diseases (NIAID)
- National Institute of Pharmaceutical Education and Research (NIPER)*
- Novartis Institute of Tropical Diseases*

LOCATION
- Canada
- India
- Singapore
- Switzerland
- USA

WHAT
- PA-824’s rapid progress in preclinical development

---

*Collaboration in discussion.
“After forty years of delays in drug development, we can’t afford to leave any stone unturned,” explains Dr. Michael Hearn, who heads a Wellesley College laboratory that is engaged in painstaking, crucial work. Along with fellow chemists Michaeline Chen and Dr. Eleanor Webster, Dr. Hearn synthesizes new molecules to improve on the best of existing treatment. By expanding the range of chemical diversity as widely and quickly as possible, Dr. Hearn hopes to stay ahead of the increasing problem of drug-resistance.

Six months into the two-year research project with the TB Alliance, Dr. Hearn has synthesized over 300 distinct molecules at Wellesley College. Emphasizing diversity, the goal is to find a path to a new drug using a wealth of existing and novel chemistry. One lead compound from this research is MJH-98-I-81, an analog of isoniazid (INH), the cornerstone of current therapy. The new compound has excellent activity in vitro against M. tuberculosis, a high selectivity index, outstanding bioavailability and potent activity in the mouse model. Other early tests show that it does not cause any gene damage.

Dr. Hearn’s new molecules also aim to lessen a problem known as xenobiotic transformation, a process whereby the human system protects itself by ridding the body of anything foreign, including medicine. This affects current anti-TB drugs, and Dr. Hearn hopes to overcome this hurdle by deepening our understanding of how INH is processed. To understand how INH, once activated, interacts with the mycobacterium, Dr. Hearn uses X-ray crystallography and TB’s genetic code to identify the exact “lock-and-key” fit between drug and a target in the bacterium, which can then guide rational drug design of novel chemical entities.

Even in a laboratory endowed with sophisticated organic chemistry equipment, Dr. Hearn is mindful of the practical challenges of delivering a new drug. To ensure affordability, he must anticipate the logistics of manufacturing, so that costs can be minimized.

Once compounds are generated, Dr. Hearn partners with biological laboratories that conduct the in vitro and in vivo studies that narrow the field of candidates and point him in the right direction. The laboratory of Dr. Michael Cynamon at the Veterans Administration Medical Center in Syracuse, New York, is one of the partners. In addition, Dr. Hearn receives support from the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) established by the NIAID.

Support from the TB Alliance has greatly accelerated Dr. Hearn’s progress. “With the tools we now have available, I know we can discover a faster cure.”
In Taejon, South Korea, Dr. Tae-Ho Park’s team at the Korea Research Institute of Chemical Technology (KRICT) has accelerated work on quinolones via a two-year agreement signed with the TB Alliance in April 2003.

KRICT, a government-funded research institute, was selected by the TB Alliance because of its excellent track record in quinolone synthesis and for its success in developing the early lead quinolone compound, KRQ-10018, which has demonstrated activity and specificity for tuberculosis.

Quinolones, a family of compounds already on the market for other indications and having great potential for the treatment of TB, may play a vital role in reducing the duration of treatment and in the treatment of drug resistant TB. Optimization of quinolones is considered a key avenue for developing new TB drugs.

With TB Alliance support, a total team of six chemists at KRICT will synthesize several hundred compounds. The compounds will then be tested in vivo and in vitro for specific activity against TB by KRICT’s partner, a biology laboratory at Yonsei University. Selected candidates will be tested in vivo, short-term and extended animal efficacy studies.

KRQ-10018, the lead compound in the family, will be further evaluated for efficacy and safety. In addition, the project aims to yield up to three other lead candidates in the TB Alliance portfolio for further development.

With rising incidences of multi-drug resistant TB, Korea is no stranger to the challenges of this global epidemic. The team at KRICT recognizes a dual-incentive behind the TB Alliance project, the first R&D partnership in Asia and the first in a country with a high TB burden.

“Korea shares the burden of TB, to which no one is immune, and we hope our contribution will be an asset to the global effort,” explained Dr. Park.
Moxifloxacin, a quinolone that has received virtually worldwide regulatory approval, has shown high levels of activity against *M. tuberculosis* in *in vitro* models. Developed by Bayer AG, the drug is currently approved for use in the U.S. for treatment of skin and upper respiratory tract infections and pneumonia. Research funded by the TB Alliance has affirmed moxifloxacin’s early promise for shorter therapy through *in vivo* experiments utilizing a murine (mouse) model developed by Dr. Jacques Grosset. Support from the TB Alliance also helps ensure that the murine model, a platform technology, will continue to be available for other TB drug development studies.

By mimicking human disease, Dr. Grosset’s world-renowned mouse model helps test drug candidates prior to undertaking clinical trials in patients. Developed at the Hôpital St. Pieté-Salpêtrière in Paris, the model was recently transferred to the Center for Tuberculosis Research at The Johns Hopkins University in Baltimore, where Dr. Grosset works with Dr. William Bishai, a TB researcher and practicing physician.

The Hopkins team substituted moxifloxacin in various combinations to replace or enhance elements of existing treatment. Dr. Grosset explains that “the next step is to confirm the *in vivo* results in clinical trials.”

In a collaboration with Bayer AG facilitated by the TB Alliance, the CDC TB Trials Consortium (TBTC) has undertaken a large Phase II clinical trial to determine the acceptability and short-term efficacy of a moxifloxacin-containing regimen for the initial treatment of patients with newly diagnosed tuberculosis. Patients are already being enrolled at TBTC sites throughout North America and Uganda. The TB Alliance is actively involved in this collaboration with the goal of assuring that resulting therapies will be available to all in need.

As leading TB scientists and former TB patients, Drs. Grosset and Bishai know first-hand the potential impact of shorter TB therapy, a driving force behind their work.
Dr. Amina Jindani maintains a fierce conviction in the role of clinical trials for developing better TB therapeutics. For her, “It is the gold standard for devising any kind of treatment. It’s the final proof. If you don’t know what happens in practice, it won’t do you much good.”

Dr. Jindani should know. In 1967, she coordinated the landmark study by the British Medical Research Council that reduced TB treatment from two years to six months. Dr. Jindani’s experience establishes her as one of the leading authorities on TB.

Based at the International Union Against Tuberculosis and Lung Disease (IUATLD), Dr. Jindani is evaluating the efficacy of TB therapy using World Health Organization—recommended fixed dose combinations (FDCs), where four drugs are combined in a single pill. Support from the TB Alliance is enabling the standardization of a network of 15 global sites, with a total of 1,500 patients, in Africa, Asia and South America.

By training staff and upgrading laboratories, Dr. Jindani’s project can also provide the TB community with a set of potential clinical trial sites and the highest standard of practical and ethical guidelines for clinical trials with new molecules.

While the first step for these clinical trials is approval by local and international ethics committees, many hurdles still exist and involve cultural, religious and political realities.

Dr. Jindani is unequivocal. “If we don’t get the patients on our side, we don’t have a trial. That’s going to be even more important when we’re testing new molecules. This is not about experimenting with people. We really want them to get better. We are caregivers.”

“Most patients do not understand what a clinical trial is, yet they are desperate for a treatment that takes only weeks, not months. Our project doubles as a way to educate patients to demand better drugs.”

Dr. Amina Jindani, IUATLD

WORKSHOP TO ADDRESS LATENCY

Since the TB bacillus was first identified, scientists have wrestled with its unusual ability to persist in an apparent non-replicating latent state. Of the world’s 1.9 billion cases of TB, 99.5% exhibit no outward symptoms, but the patients still carry the bacterium that causes TB. Complicating matters is the apparent response of the human immune system to the bacterium and its interaction with HIV/AIDS: people co-infected with latent TB and HIV/AIDS are 30–50 times more likely to convert latent TB into the active, transmissible form of tuberculosis.

This dire public health situation raises some vexing questions: What causes the bacillus to go “active”? How critical is the immune system response? What is the bacillus doing in a persistent state? How can we begin to answer these questions, and what do they mean for the design of better drugs?

Early research suggests that non-replicating bacteria behave similarly in active and latent cases. The hope is that drugs developed to fight persistent bacteria will ultimately prove effective in treating latent disease and thereby reduce the length of treatment of both active and latent TB.

Providing drugs that suffice when taken for a relatively short period of time will ensure that more patients comply with the full course of therapy and thereby receive proper treatment. This will limit the opportunity for the bacterium to evolve into strains resistant to current antibiotics.

Shorter therapy would also allow many more cases of latent infection to be treated before they become active cases, boosting efforts now underway to treat those co-infected with HIV and lower the transmission of active TB.

The TB Alliance convened a workshop in January 2003 to address these questions and begin to identify key latency targets. At this meeting a group of leading TB scientists discussed initial strategies to tackle latency and chart a course for new drug development.

This workshop was co-chaired by Dr. Clifton Barry of the NIAID and Dr. Peter Small of the Bill and Melinda Gates Foundation.
ENLISTING GLOBAL EXPERTISE

The development of a new TB medicine is a global endeavor. To fulfill its mission, the TB Alliance builds on existing networks and mobilizes industry, public and academic researchers worldwide.

Africa

SOUTH AFRICA MEDICAL RESEARCH COUNCIL
Hosting the office in South Africa, the Medical Research Council (MRC) is a key partner of the TB Alliance, providing expertise to the SAC and actively participating as a Stakeholder. The MRC helped establish the South African Clinical Trials Consortium to upgrade clinical capacity, a critical foundation for anticipated TB clinical trials.

Americas

UNITED STATES SCIENCE AND INDUSTRY NETWORKS
The TB Alliance leverages scientific expertise, facilities and research capacity in academic, industrial and public research laboratories throughout the United States. In-kind support, as provided by NIAID, and contractual outsourcing arrangements are helping the TB Alliance develop its portfolio. Through early R&D partnerships, as well as board members and scientific advisors from industry, the TB Alliance is assessing innovative strategies to further tap pharmaceutical and biotechnology companies.

BRAZIL & PERU PRECLINICAL AND CLINICAL EXPERTS
A strong R&D commitment and extensive TB research network, coupled with an increasing prevalence of TB, make Brazil and Peru natural partners for the TB Alliance. After visiting laboratories, clinical trial sites and manufacturing facilities, the TB Alliance is in partnership discussions with several Brazilian and Peruvian organizations.
Asia

JAPAN SCIENCE AND INDUSTRY NETWORKS
Japan recognizes TB as both a domestic and a global health issue and spearheaded the G-8 commitment on infectious diseases. The TB Alliance works closely with the Research Institute of Tuberculosis (RIT) of the Japan Anti-TB Association (JATA), a Stakeholder, and the Kyoto Pharmaceutical University. The TB Alliance is also in discussions with Japanese companies to establish R&D partnerships.

KOREA KRICT AND YONSEI UNIVERSITY
Bolstering the TB Alliance’s portfolio of drug candidates, KRICT and Yonsei University in Taegon are optimizing novel quinolones and exploring new quinolizines and pyridones to treat TB.

INDIA SCIENCE, INDUSTRY AND CLINICAL NETWORKS
India’s chemical, pharmaceutical and clinical research experts are critical to the development of new drugs. The TB Alliance is building strong alliances there and is currently negotiating partnerships for the development of promising compounds.

Europe

EUROPEAN UNION EDCTP
In 2003, the European and Developing Countries Clinical Trials Partnership (EDCTP) was launched to support Phase II and III trials in, with and for developing countries, with a focus on AIDS, TB and malaria. This expansion of laboratory and human capacity will be critical to upcoming TB drug clinical trials.

EUROPE NEW DEVELOPMENTS WITH INDUSTRY
• The TB Alliance catalyzed a groundbreaking meeting between Bayer AG and CDC on a clinical trial of moxifloxacin for first-line TB treatment.
• Basel-based Novartis launched its Institute for Tropical Diseases in Singapore, pledging to collaborate with the TB Alliance in the development of novel TB compounds.
• GlaxoSmithKline seconded Dr. Ken Duncan, an expert in TB drug discovery, to the TB Alliance.

Europe

EUROPEAN UNION EDCTP
In 2003, the European and Developing Countries Clinical Trials Partnership (EDCTP) was launched to support Phase II and III trials in, with and for developing countries, with a focus on AIDS, TB and malaria. This expansion of laboratory and human capacity will be critical to upcoming TB drug clinical trials.

EUROPE NEW DEVELOPMENTS WITH INDUSTRY
• The TB Alliance catalyzed a groundbreaking meeting between Bayer AG and CDC on a clinical trial of moxifloxacin for first-line TB treatment.
• Basel-based Novartis launched its Institute for Tropical Diseases in Singapore, pledging to collaborate with the TB Alliance in the development of novel TB compounds.
• GlaxoSmithKline seconded Dr. Ken Duncan, an expert in TB drug discovery, to the TB Alliance.
This year, the world celebrated the completion of the sequencing of the human genome, one of the greatest scientific achievements of our time. Yet, this year, we also saw the rise of the highest levels of tuberculosis ever, now infecting one-third of the world’s population and killing one person every 15 seconds.

This juxtaposition between today’s stark global health situation and remarkable scientific progress highlights the critical role of the TB Alliance as we bridge these two realities in our quest to develop novel, faster anti-TB drugs. Every project we undertake engages the best minds, laboratories and facilities in the pursuit of an affordable, faster cure. We know that the TB Alliance occupies a unique place in the world because our mission and our strategy combine technical objectives with social goals.

Therefore, we are pleased to report that this year the TB Alliance has made great strides in the search for a novel, faster TB drug. This report highlights some of the accomplishments and progress realized over the past year and provides an overview of our fast-paced and exciting activities.

Our investments of human capital and financial resources are designed to maximize efficiencies and speed results. Driven by a commitment to health equity, we operate under the same drug development guidelines as the best models of the private sector. Our criteria center on whether a compound can make a marked, profound improvement in the treatment of TB to all patients in need. Our ultimate accountability in this enterprise rests with the one-third of the world infected with TB.

The TB Alliance assembles and manages a portfolio of promising compounds, carefully selected from a wide range of public, private and academic facilities. To ensure a successful, global, cooperative enterprise, we catalyze the involvement of researchers all over the world and invest in platform technologies that accelerate scientific progress. Through our leadership on the Stop TB Working Group on New Drugs, we ensure that others benefit from these platform technologies, share information and collaborate to achieve our goal.

Under the skillful direction of Dr. Mel Spigelman, our R&D team is swiftly identifying and accessing portfolio compounds, while capitalizing on private and public resources for development activities. Through our ongoing evaluations of clinical trial and drug development capacity around the world, we further position the TB Alliance for the rapid clinical validation of promising compounds.

We have built a growing portfolio with diverse compounds. The lead investment, PA-824, is recognized as one of the most promising novel compounds for TB treatment. With generous support from the U.S. National Institute of Allergy and Infectious Diseases (NIAID), this compound is progressing quickly through key preclinical development milestones. Similar strategic outsourcing will help to develop the analogs of PA-824, a project we are in the process of finalizing with partners.

On parallel tracks, our investments in innovative chemistry are helping to optimize quinolones at Korea Research Institute of Chemical Technology (KRICT) and to refine an isoniazid analog in the United States; both efforts are targeted to improve first-line drugs. Additionally, our most recent Request for Proposals has led to the identification of new lead compounds with the potential to further enhance our portfolio.

We are also exploring the use of existing drugs such as moxifloxacin in first-line therapy which could help shorten therapy for TB in the near term. Finally, in funding projects for murine models and clinical trial capacity, we provide essential infrastructure support to the community of TB drug researchers worldwide.
OVERVIEW OF TB ALLIANCE APPROACH

The TB Alliance selects and manages a portfolio of drug candidates that are outsourced to industry, academia and public laboratories for development. We invest in process development and clinical infrastructure for TB drug development to facilitate discovery and development by the TB Alliance and third parties. Our innovative agreements with R&D partners accelerate research and development and ensure affordability of the drugs developed.

In 2002-2003, three leading pharmaceutical companies pledged to enhance TB research. These investments help support the work of the TB Alliance in concrete ways. GlaxoSmithKline is contributing drug discovery expertise by seconding Dr. Ken Duncan, the architect of its Action TB program, to the TB Alliance. AstraZeneca and the TB Alliance co-hosted a conference on TB drug development at AstraZeneca’s TB research facility in Bangalore, India. We especially welcome the commitment of Novartis to provide us with core R&D support, using the newly created Novartis Institute for Tropical Diseases, as well as its pledge of royalty-free pricing in endemic countries.

The TB Alliance capitalizes on the newest scientific advances to generate novel drug candidates. In recent years, a wealth of new scientific information on TB has been forthcoming, including a better understanding of the interaction between the mycobacterium and the human host as it relates to latent infection. To address the challenges of latency in the context of drug development, we hosted a scientific workshop to explore possible strategies and to identify top drug targets for TB latency. The results of this meeting, to be reported in a scientific publication, provided the basis for a submission to the Grand Challenges in Global Health initiative of the Bill and Melinda Gates Foundation.

As recognition of global health priorities increases, we have witnessed growing consensus around the goals of the TB Alliance from leaders in science, business and policy. Yet, translating this consensus into concrete results depends on everyone’s support and involvement. As a public-private partnership, we engage a wide circle of participants in our endeavor. This year’s accomplishments reflect the continued support of our donors, the counsel of our Scientific Advisory Committee and the global reach of our Stakeholder network. Our staff, expanding in scope and expertise, is comprised of dedicated individuals who ensure we meet our milestones and enlist strategic partners to achieve our mission.

The TB Alliance has conceived of creative ways to partner with pharmaceutical and biotechnology companies with drug development know-how and capacity. Likewise, we have established strong links with public research organizations and with advocacy groups worldwide. And our enterprise relies on a firm commitment from donor governments to the Global Plan to Stop TB to ensure effective TB control through the new drugs that promise dividends on a profound scale.

As we fully grasp an impending global health catastrophe—the twin TB-HIV epidemic combined with the rise of multi-drug resistant strains—we must redouble our efforts to bridge the gap between the promises of science and the need of millions worldwide.

This is no small task, yet the returns are equal to the energy and resources required to turn this vision into reality. Together we have a chance to turn a daring experiment into a legacy.

Maria C. Freire, Ph.D
Chief Executive Officer

Seán P. Lance,
Chairman, Chiron Corporation
Chairman of the Board of Directors
**Board of Directors**

Dr. Gail Cassell  
Vice President and Distinguished Fellow, Eli Lilly and Company

Dr. Gijs Elzinga  
Deputy Director-General, Netherlands’ National Institute of Public Health and the Environment

Dr. Maria C. Freire  
Chief Executive Officer, Global Alliance for TB Drug Development

Mr. Charles Kaye, Treasurer  
Co-President, Warburg Pincus

Mr. Seán Lance, Chair  
Chairman of the Board, Chiron Corporation

Dr. William Makgoba  
Vice Chancellor and Principal, University of Natal, South Africa

Dr. John La Montagne  
Deputy Director, National Institute of Allergy and Infectious Diseases

Dr. Carlos Morel, Vice Chair  
Director, Special Programme for Research and Training in Tropical Diseases/World Health Organization

Dr. Lee Reichman  
President of the Stakeholders Association, Executive Director, New Jersey Medical School National Tuberculosis Center

Dr. Ariel Pablos-Méndez, Secretary  
Acting Director, Health Equity Rockefeller Foundation

**Scientific Advisory Committee**

Dr. Clifton Barry, Ill  
National Institute of Allergy and Infectious Diseases

Dr. Ken Duncan  
GlaxoSmithKline

Dr. Bernard Fourie, Secretary  
Medical Research Council of South Africa

Dr. Maria C. Freire  
Global Alliance for TB Drug Development

Dr. Jacques Grosset  
The Johns Hopkins University

Dr. John Horton  
GlaxoSmithKline (ret.)

Dr. Yoshiaki Kiso  
Kyoto Pharmaceutical University

Dr. Barbara Laughon, Co-Chair  
National Institute of Allergy and Infectious Diseases

Dr. Christopher Lipinski  
Pfizer Inc. (ret.)

Dr. Denis Mitchison  
St. George’s Hospital Medical School

Dr. Richard O’Brien, Chair  
Centers for Disease Control and Prevention

Dr. Ramesh Panchagnula  
Indian National Institute of Pharmaceutical Education and Research

Dr. Christine Sizemore  
National Institute of Allergy and Infectious Diseases

Dr. C. Ken Stover  
Pfizer Inc.

**Staff and Consultants**

Dr. Maria C. Freire  
Chief Executive Officer

Dr. Mel Spigelman  
Director, Research and Development

Ms. Joelle Tanguy  
Director, Advocacy and Public Affairs

Mr. Brad Jensen  
Director, Finance and Administration

Ms. Katie Cecil  
Program Assistant

Mr. Serdar Elmali  
Information Technology and Networking Consultant

Ms. Beatrice Evangelista  
Officer, Public Affairs

Ms. Beverly Fulk  
Executive Secretary to the CEO

Dr. Marilyn Hartig  
Consultant, Industry Relations

Ms. Muntaha Sabah Lazim  
Administrative Manager

Ms. Gwynne Oosterbaan  
Assistant Director, Public Affairs

Dr. Doris Rouse  
Portfolio Project Manager

Dr. Gerald J. Siuta  
Consultant, Business Development

Ms. Karen M. Wright  
Senior Advisor
JOIN US IN THE SEARCH FOR A FASTER CURE
Independent Auditors’ Report

BOARD OF DIRECTORS OF
THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC.

We have audited the accompanying statement of financial position of the Global Alliance for TB Drug Development, Inc. as of December 31, 2002, and the related statements of activities, functional expenses and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Global Alliance for TB Drug Development, Inc. as of December 31, 2002, and the changes in its net assets and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

Information for the year ended December 31, 2001 is presented for comparative purposes only and was extracted from the financial statements of the Global Alliance for TB Drug Development, Inc. for that year, which were audited by other auditors whose report, dated June 14, 2002, expressed an unqualified opinion on those statements.

June 9, 2003

Statement of Financial Position
(with comparative totals for 2001)

DECEMBER 31, 2002 2001

ASSETS
Cash and cash equivalents (Note 2) $22,367,458 $17,031,287
Cash - restricted (Notes 2 and 6) 125,087 119,888
Other assets 165,434 147,712
Property and equipment, net (Notes 2 and 4) 134,958 208,260

$22,792,937 $17,507,147

LIABILITIES AND NET ASSETS
Liabilities
Accounts payable and other liabilities $210,954 $320,801
Accrued payroll and payroll-related liabilities 29,968 —
Capital lease obligation (Note 6) 88,581 112,074
Deferred revenue (Note 5) 1,800,000 1,875,000
Total liabilities 2,129,503 2,307,875

COMMITMENTS (NOTE 7)
Net assets
Unrestricted net assets 20,663,434 15,199,272

$22,792,937 $17,507,147

See accompanying notes to financial statements.
Statement of Activities
(with comparative totals for 2001)

YEAR ENDED DECEMBER 31,

PUBLIC SUPPORT AND OTHER REVENUE:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$8,441,731</td>
<td>$7,000,000</td>
</tr>
<tr>
<td>Contributed services (Note 3)</td>
<td>268,460</td>
<td>598,738</td>
</tr>
<tr>
<td>Interest and dividend income</td>
<td>308,055</td>
<td>177,151</td>
</tr>
<tr>
<td>Net realized and unrealized gain on investments</td>
<td>—</td>
<td>296,784</td>
</tr>
<tr>
<td>Miscellaneous income</td>
<td>227</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total public support and other revenue</strong></td>
<td>9,018,473</td>
<td>8,072,673</td>
</tr>
</tbody>
</table>

EXPENSES:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and development</td>
<td>1,510,522</td>
<td>1,012,526</td>
</tr>
<tr>
<td>Business development</td>
<td>333,817</td>
<td>53,616</td>
</tr>
<tr>
<td>Advocacy</td>
<td>826,805</td>
<td>727,066</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>2,671,144</td>
<td>1,793,208</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>839,169</td>
<td>866,841</td>
</tr>
<tr>
<td>Fundraising</td>
<td>116,472</td>
<td>74,413</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>955,641</td>
<td>941,254</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>3,626,785</td>
<td>2,734,462</td>
</tr>
<tr>
<td>Change in net assets before foreign translation gain (loss)</td>
<td>5,391,688</td>
<td>5,338,211</td>
</tr>
</tbody>
</table>

FOREIGN TRANSLATION GAIN (LOSS) (NOTE 2)

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>72,474</td>
<td>(13,468)</td>
</tr>
</tbody>
</table>

CHANGE IN NET ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>5,464,162</td>
<td>5,324,743</td>
</tr>
</tbody>
</table>

NET ASSETS, BEGINNING OF YEAR

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>15,199,272</td>
<td>9,874,529</td>
</tr>
</tbody>
</table>

NET ASSETS, END OF YEAR

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>$20,663,434</td>
<td>$15,199,272</td>
</tr>
</tbody>
</table>

---

Statement of Cash Flows
(with comparative totals for 2001)

YEAR ENDED DECEMBER 31,

CASH FLOWS FROM OPERATING ACTIVITIES:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
<td>$5,464,162</td>
<td>5,324,743</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net realized gain from investments</td>
<td>—</td>
<td>(306,240)</td>
</tr>
<tr>
<td>Net unrealized loss from investments</td>
<td>—</td>
<td>9,456</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>100,176</td>
<td>34,553</td>
</tr>
<tr>
<td>Increase in assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted cash</td>
<td>(5,199)</td>
<td>(119,888)</td>
</tr>
<tr>
<td>Security deposits and other receivables</td>
<td>(17,722)</td>
<td>(144,612)</td>
</tr>
<tr>
<td>Increase (decrease) in liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and other liabilities</td>
<td>(109,847)</td>
<td>2,770</td>
</tr>
<tr>
<td>Accrued payroll and related liabilities</td>
<td>29,968</td>
<td>—</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(75,000)</td>
<td>(375,000)</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>5,386,538</td>
<td>4,425,782</td>
</tr>
</tbody>
</table>

CASH FLOWS FROM INVESTING ACTIVITIES:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchase of investments</td>
<td>—</td>
<td>(10,250,072)</td>
</tr>
<tr>
<td>Proceeds from sale of investments</td>
<td>—</td>
<td>19,156,136</td>
</tr>
<tr>
<td>Additions to property and equipment</td>
<td>(26,874)</td>
<td>(58,998)</td>
</tr>
<tr>
<td><strong>Net cash provided by (used in) investing activities</strong></td>
<td>(26,874)</td>
<td>8,847,066</td>
</tr>
</tbody>
</table>

CASH FLOWS FROM FINANCING ACTIVITIES:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repayments of capital lease obligation</td>
<td>(23,493)</td>
<td>(10,923)</td>
</tr>
</tbody>
</table>

NET INCREASE IN CASH AND CASH EQUIVALENTS

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>5,336,171</td>
<td>13,261,925</td>
</tr>
</tbody>
</table>

CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>17,031,287</td>
<td>3,769,362</td>
</tr>
</tbody>
</table>

CASH AND CASH EQUIVALENTS, END OF YEAR

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>22,367,458</td>
<td>17,031,287</td>
</tr>
</tbody>
</table>

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

<table>
<thead>
<tr>
<th>Description</th>
<th>2002</th>
<th>2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash paid for interest</td>
<td>6,200</td>
<td>6,407</td>
</tr>
<tr>
<td>Noncash transactions related to capital lease</td>
<td>—</td>
<td>122,997</td>
</tr>
</tbody>
</table>

See accompanying notes to financial statements.
Notes to Financial Statements

1. ORGANIZATION

The Global Alliance for TB Drug Development, Inc. ("TB Alliance") is a nonprofit organization incorporated on July 24, 2000 under the General Corporation Law of Delaware and authorized to conduct business in New York under the Not-for-Profit Corporation Law of New York. It operates as a not-for-profit, with offices in Brussels, Cape Town and New York.

The TB Alliance was formed to accelerate the development of effective new medicines to treat tuberculosis (TB) and ensure their affordability and availability in high-endemic countries.

Advocating for a worldwide mobilization against the TB epidemic through innovative research into new therapeutics, the TB Alliance develops innovative partnerships and involves scientists and researchers globally. It builds a portfolio of promising drug candidates and outsources research and development projects to public and private labs to develop affordable new drugs that will shorten the treatment of tuberculosis, be effective against multi-drug resistant strains and improve treatment of latent infection.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation
The financial statements have been prepared on the accrual basis.

Financial Statement Presentation
The classification of a not-for-profit organization’s net assets and its support, revenue and expenses is based on the existence or absence of donor-imposed restrictions. It requires that the amounts for each of three classes of net assets, permanently restricted, temporarily restricted, and unrestricted, be displayed in a statement of financial position and that the amounts of change in each of those classes of net assets be displayed in a statement of activities.

Income from investment gains and losses, including unrealized gains and losses, dividends, interest and other investments should be reported as increases (or decreases) in unrestricted net assets unless the use of the income received is limited by donor-imposed restrictions.

These classes are defined as follows:

- **Permanently Restricted** — Net assets resulting from contributions and other inflows of assets whose use by TB Alliance is limited by donor-imposed stipulations that neither expire by passage of time nor can be fulfilled or otherwise removed by actions of TB Alliance.
- **Temporarily Restricted** — Net assets resulting from contributions and other inflows of assets whose use by TB Alliance is limited by donor-imposed stipulations that either expire by passage of time or can be fulfilled and removed by actions of TB Alliance pursuant to those stipulations. When such stipulations end or are fulfilled, such temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities.
- **Unrestricted** — The part of net assets that is neither permanently nor temporarily restricted by donor-imposed stipulations.

Cash and Cash Equivalents
TB Alliance considers short-term investments with original maturities of three months or less to be cash equivalents.

Restricted Cash
Restricted cash consists of cash held by banks providing collateral for TB Alliance’s leased equipment.

Investments
Investments are valued at fair value in the statement of financial position. Unrealized gains and losses are included in the statement of activities.

Depreciation and Amortization
The cost of property and equipment is depreciated over the estimated useful lives of the assets using the straight-line method. Leasehold improvements are amortized over the lesser of the life of the lease or asset. The estimated useful lives of the assets are as follows:

- **Computer equipment**: 3 — 5 years
- **Furniture and equipment**: 3 — 5 years
- **Leasehold improvements**: 5 — 10 years

Income Taxes
TB Alliance is exempt from federal and state income taxes under Section 501(c)(3) of the Internal Revenue Code (the “Code”) and therefore has made no provision for income taxes in the accompanying financial statements. The Internal Revenue Service (the “IRS”) has made a determination that TB Alliance can be treated as a publicly supported organization described in Code Sections 509(a)(1) and 170(b)(1)(A)(vi) during an advance ruling period beginning on July 24, 2000 and ending December 31, 2004. After the advance ruling period, the IRS will make a final determination of TB Alliance’s public charity status. There was no unrelated business income for 2002.

Contributions and Promises to Give
Contributions and promises to give are recorded as revenue when either unsolicited cash is received or when donors make a promise to give. Contributions and promises to give are classified as either unrestricted, temporarily restricted or permanently restricted support.

Contributed Goods and Services
Contributed goods and services are recognized as revenue and expenses if such goods and services meet the criteria for recognition as stated in Statement of Financial Accounting Standards (“SFAS”) No. 116, “Accounting for Contributions Received or Contributions Made.”

Program Services
Research and Development — TB Alliance creates and manages a portfolio of new anti-TB drug candidates by identifying, evaluating and acquiring promising molecules from scientific laboratories worldwide and outsourcing their development to appropriate public and private partners. Further, TB Alliance invests in infrastructure research projects that accelerate anti-TB drug development and analyzes existing scientific gaps to address these as part of the overall development strategy.

Business and Organizational Development — TB Alliance negotiates, implements and manages agreements with public and private organizations worldwide and does so by adhering to sound business practices while ensuring the public good. Specifically, TB Alliance negotiates terms that support the development and access of new, affordable anti-TB drugs equitably to those areas most in need while encouraging the private sector to help develop new medicines for TB indications.

Advocacy — TB Alliance manages critical alliances with public and private organizations to raise awareness about TB and advocate for public and private involvement in research for new anti-TB medicines. It develops landmark studies to support policy developments seeking to accelerate anti-TB drug research and mobilizes networks of researchers and investigators worldwide to focus on the development of these medicines.

Use of Estimates
In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

Comparative Financial Information
The financial statements include certain prior year summarized comparative information. Such information does not include sufficient detail to constitute a presentation in conformity with generally accepted accounting principles. Accordingly, such information should be read in conjunction with the prior year financial statements from which summarized information was derived.

Concentration of Credit Risk
Financial instruments which potentially subject TB Alliance to concentration of credit risk consist primarily of temporary cash investments. At various times during the year, TB Alliance had cash deposits at financial institutions which exceeded the FDIC insurance limit.

Reclassifications
Certain prior year amounts have been reclassified to be consistent with the current year financial statements presentation.

Foreign Currency Translation
All elements of the financial statements reflecting TB Alliance’s operations

22
in Brussels are translated into U.S. dollars using applicable exchange rates. For assets and liabilities, this is the rate in effect at the statement of financial position date. For revenue and expense items, translation is performed monthly using the average rate for the month. The exchange rate as of December 31, 2002 was 1.0483 EUR/USD.

Foreign currency is translated in accordance with the provisions of SFAS No. 52, “Foreign Currency Translation.” Under the provisions of SFAS No. 52, the local currency used in TB Alliance’s foreign operations is considered to be the functional currency of these operations. Translation of the financial statements of these operations resulted in a translation gain (loss) as follows:

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>DECEMBER 31, 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cumulative translation loss adjustment, beginning of period</td>
<td>(13,468)</td>
</tr>
<tr>
<td>Translation adjustment</td>
<td>72,474</td>
</tr>
<tr>
<td>Cumulative translation gain adjustment, end of period</td>
<td>59,006</td>
</tr>
</tbody>
</table>

The cumulative translation gain is included in unrestricted net assets.

3. CONTRIBUTED SERVICES

Included in TB Alliance’s statement of activities is approximately $270,000 and $600,000 for the years ended December 31, 2002 and 2001, respectively, of in-kind contributions.

The amounts recognized during the year ended December 31, 2002 were related to project management costs. The amounts recognized in 2001 were related to TB Alliance’s research, development, publication and distribution of a scientific study, the “Scientific Blueprint for TB Drug Development,” and a market research and costs study titled, “Economics of TB Drug Development.”

4. PROPERTY AND EQUIPMENT, NET

Property and equipment, net, stated at cost, consists of the following:

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>DECEMBER 31, 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computer equipment</td>
<td>$ 67,498</td>
</tr>
<tr>
<td>Furniture and equipment</td>
<td>129,545</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>12,354</td>
</tr>
<tr>
<td>Total property and equipment</td>
<td>209,397</td>
</tr>
<tr>
<td>Less: Accumulated depreciation and amortization</td>
<td>(74,439)</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>$ 134,958</td>
</tr>
</tbody>
</table>

5. SUPPORT

On September 8, 2000, the Bill and Melinda Gates Foundation approved a five-year unrestricted grant to TB Alliance in the amount of $25,000,000 for use in furtherance of its overall charitable purpose and mission to improve the supply of anti-TB drugs for national TB control efforts and to develop a collaboration for TB drug development. The statement of activities includes $5,000,000 as unrestricted contributions for each of the years ended December 31, 2002 and 2001, respectively, for funds received. As of December 31, 2002, the Bill and Melinda Gates Foundation has paid TB Alliance the sum of $20,000,000 of the $25,000,000. The remaining $5,000,000 is a conditional grant expected to be paid to TB Alliance in one future annual payment upon the achievement of certain milestones.

On December 22, 2000, the Rockefeller Foundation approved a general support grant to TB Alliance of up to $4,500,000 for 2001, for which an extension was granted in November 2001 to extend the period of availability to December 31, 2002 with any unused grant funds reverting back to the Rockefeller Foundation. The statement of activities includes $2,500,000 and $2,000,000 as unrestricted contributions for the years ended December 31, 2002 and 2001, respectively.

On November 30, 2001, the Rockefeller Foundation announced a second general support grant to TB Alliance for up to $3,500,000 for the one-year period beginning August 1, 2002, with any unused funds reverting back to the Rockefeller Foundation at the end of the grant period. As of December 31, 2002, the Rockefeller Foundation had paid TB Alliance the sum of $1,750,000 of the $3,500,000. This advancement is included in deferred revenue as of December 31, 2002. TB Alliance anticipates spending the entire grant by July 31, 2003.

On October 9, 2002, the World Health Organization approved a general support grant to TB Alliance for up to 2,007,876 Euros for the two-year period beginning January 1, 2002 with any unused funds reverting back to the World Health Organization at the end of the grant period. As of December 31, 2002, the World Health Organization had paid TB Alliance the sum of 1,003,938 Euros of the 2,007,876 Euros which was equivalent to $988,277 at the funds received date. As of December 31, 2002, unspent remaining funds are included in deferred revenue.

6. CAPITAL LEASE OBLIGATION

At December 31, 2002, capital lease obligation consisted of the following:

<table>
<thead>
<tr>
<th>DESCRIPTION</th>
<th>DECEMBER 31, 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB Alliance financed the cost of certain equipment with a lease obligation in various monthly installments of $2,475 until May 2006, including interest at 7.96% secured by restricted cash accounts totalling $125,087</td>
<td>$ 88,581</td>
</tr>
<tr>
<td>Less: Current maturities</td>
<td>23,491</td>
</tr>
<tr>
<td></td>
<td>$ 65,090</td>
</tr>
</tbody>
</table>

Future minimum lease payments due under these capital lease obligations at December 31, 2002 are as follows:

<table>
<thead>
<tr>
<th>YEAR ENDING DECEMBER 31, 2002</th>
<th>DECEMBER 31, 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>$ 23,491</td>
</tr>
<tr>
<td>2004</td>
<td>25,430</td>
</tr>
<tr>
<td>2005</td>
<td>27,529</td>
</tr>
<tr>
<td>2006</td>
<td>12,131</td>
</tr>
<tr>
<td>2007</td>
<td>$ 88,581</td>
</tr>
</tbody>
</table>

7. COMMITMENTS

TB Alliance has operating lease agreements for office space in New York, Brussels and Cape Town for various terms expiring in November 2009. The following is a schedule of future minimum rental payments under the above operating leases as of December 31, 2002:

<table>
<thead>
<tr>
<th>YEAR ENDING DECEMBER 31, 2002</th>
<th>DECEMBER 31, 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>$ 224,809</td>
</tr>
<tr>
<td>2004</td>
<td>214,584</td>
</tr>
<tr>
<td>2005</td>
<td>213,552</td>
</tr>
<tr>
<td>2006</td>
<td>86,288</td>
</tr>
<tr>
<td>2007</td>
<td>43,866</td>
</tr>
<tr>
<td>Thereafter</td>
<td>84,077</td>
</tr>
<tr>
<td></td>
<td>$ 867,176</td>
</tr>
</tbody>
</table>

TB Alliance has research and development agreements with several research institutions to fund various research and development contracts useful for treatment of TB. The agreements’ expiration dates are undeterminable as of December 31, 2002. The following is a schedule of future minimum research and development payments under the above agreements as of December 31, 2002:

<table>
<thead>
<tr>
<th>YEAR ENDING DECEMBER 31, 2002</th>
<th>DECEMBER 31, 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>$ 1,509,111</td>
</tr>
<tr>
<td>2004</td>
<td>1,441,561</td>
</tr>
<tr>
<td>2005</td>
<td>575,000</td>
</tr>
<tr>
<td>2006</td>
<td>500,000</td>
</tr>
<tr>
<td>2007</td>
<td>500,000</td>
</tr>
<tr>
<td>Thereafter</td>
<td>500,000 per year</td>
</tr>
</tbody>
</table>

8. RELATED PARTIES

A member of the Board of Directors of TB Alliance is an employee of the Rockefeller Foundation, a grantor of TB Alliance.

Another member of the Board of Directors of TB Alliance is affiliated with Chiron Corporation, a company from whom the TB Alliance has licensed rights to a family of compounds.
Stakeholders

The following institutions formally pledged to accelerate the development of TB drugs. They advise, guide and support the efforts of the Global Alliance for TB Drug Development:

- American Lung Association (ALA)
- American Society for Tuberculosis Education and Research (ASTER)
- American Thoracic Society (ATS)
- Association of the British Pharmaceutical Industry (ABPI)
- Bill and Melinda Gates Foundation
- Centers for Disease Control and Prevention (CDC)
- European Commission
- Global Forum for Health Research
- International Union Against Tuberculosis and Lung Disease (IUATLD)
- Lupin Laboratories
- Médecins Sans Frontières-Doctors without Borders (MSF)
- Medical Research Council of South Africa (MRC)
- National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIAID/NIH)
- National Institute of Pharmaceutical Education and Research, India (NIPER)
- New Jersey Medical School National Tuberculosis Center
- Novartis India, Ltd
- Partners in Health
- Philippines Coalition Against Tuberculosis (PHILCAT)
- Research Institute of Tuberculosis, Japan Anti-TB Association (RIT/JATA)
- Research Triangle Institute (RTI)
- Rockefeller Foundation
- Royal Netherlands Tuberculosis Association (KNCV)
- Sequella Global Tuberculosis Foundation
- Stop TB
- U.K. Department for International Development (DFID)
- U.N. Programme for Research and Training in Tropical Diseases (TDR)
- U.S. Agency for International Development (USAID)
- Wellcome Trust
- World Bank
- World Health Organization

Acknowledgments

The Global Alliance for TB Drug Development gratefully acknowledges the generosity of the following institutions that provided key funding or in-kind support and expertise last year:

- Bill and Melinda Gates Foundation
- Rockefeller Foundation
- Netherlands Ministry for Development Cooperation
- World Health Organization
- National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Centers for Disease Control and Prevention
- GlaxoSmithKline
- Medical Research Council of South Africa
- Research Triangle Institute

The Global Alliance for TB Drug Development expresses its gratitude to all of the generous individuals who have chosen to support its mission with charitable contributions.

The Global Alliance for TB Drug Development is a not-for-profit, tax-exempt organization recognized under section 501(c)(3) of the United States Revenue Code; and contributions are tax-deductible in the United States. Its Belgium branch office was also registered in the Annex of the Belgian State Gazette for non-profit organizations on February 28, 2002.
IT’S TIME TO FIND A FASTER CURE FOR TUBERCULOSIS

DONATE
ADVOCATE
PARTICIPATE

Join this novel partnership where the talents of every individual, organization and nation will help make tuberculosis a thing of the past.

Visit www.tballiance.org to learn more.